Tuesday, July 1, 2025 7/1/2025

FOXP3 ΔE2 isoform in asthma severity and persistence

Award Number: R01AI180518
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/04/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

FOXP3 ΔE2 isoform in asthma severity and persistence - PROJECT SUMMARY FOXP3 is a key transcription factor for the development and function of regulatory T cells (Tregs) and amorphic mutations at this locus in humans and mice lead to systemic autoimmune diseases and allergic symptoms. Human FOXP3 encodes two major isoforms, a full length (FOXP3 FL isoform) and an alternatively spliced isoform lacking exon 2 (FOXP3 ∆E2 isoform), while mouse Foxp3 gene only produces the FOXP3 FL isoform. The roles of these two isoforms in health and disease have not been clearly defined. We generated mice with Foxp3 exon 2 deletion (Foxp3dE2) to study the functionality of FOXP3 ΔE2 isoform in vivo and demonstrated that expression of FOXP3 ΔE2 isoform resulted in significantly more severe allergic airway inflammation after repeated intranasal allergen (both OVA and HDM) challenge compared with wild type mice expressing only the FOXP3 FL isoform. Despite having comparable suppressive function to FOXP3 FL Tregs, FOXP3 ΔE2 Tregs are less stable and have greater propensity to transdifferentiate into T helper cells. Furthermore, FOXP3 ΔE2 Tregs express higher levels of Il4 and Il9 than FOXP3 FL Tregs. We hypothesize that dysregulated FOXP3 isoform expression in airway Tregs (i.e. elevated FOXP3 ΔE2 expression) is one of the risk factors for asthma persistence and severity. We will test our hypothesis in the following three specific aims using unique mouse strains developed in our lab: WT (Foxp3FL) mice expressing only the FOXP3 FL isoform, Foxp3dE2 mice expressing only the FOXP3 ΔE2 isoform, and humanized Foxp3huE2 mice co- expressing both isoforms through alternative splicing as in humans. (1) Define the role of the FOXP3 isoforms in severity and persistence of allergic airway inflammation. We will determine the severity of airway inflammation, Treg phenotypes, and FOXP3 isoform expression in Foxp3FL, Foxp3dE2 and Foxp3huE2 mice after chronic exposure to allergens. (2) Elucidate the mechanism of FOXP3 isoform regulation of Th9 differentiation. We will determine, at the molecular and cellular level, how FOXP3 affects Th9 differentiation and Treg to Th9 transdifferentiation. (3) Define the association of FOXP3 isoform expression with human asthma severity. We will examine the expression of human FOXP3 isoforms in patients with asthma and test whether FOXP3 isoform expression correlates with disease severity and impacts Th9 and Th17 differentiation. The information learned from these studies will provide novel insights into the physiological functions of these two naturally existing human FOXP3 isoforms and would pave the way to develop efficient clinical protocols aimed at prevention/treatment of allergic diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $776,962 )
2025	2025	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Allergy and Infectious Diseases Research	000	2	4/25/2025	NON-COMPETING CONTINUATION	$776,962
														Subtotal = $776,962

Issue Date FY: 2024 ( Subtotal = $776,962 )
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Allergy and Infectious Diseases Research	001	1	9/3/2024	NEW	$77,696
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Allergy and Infectious Diseases Research	000	1	6/4/2024	NEW	$699,266
														Subtotal = $776,962

Grand Total All Awards = $1,553,924

Top

All Categories

About

Search

Reports

Data Submission

Award Information

FOXP3 ΔE2 isoform in asthma severity and persistence

Award Number: R01AI180518

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/04/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer